AstraZeneca PLC Valuation

0A4J Stock   63.80  1.80  2.74%   
At this time, the firm appears to be undervalued. AstraZeneca PLC ADR shows a prevailing Real Value of USD76.43 per share. The current price of the firm is USD63.8. Our model approximates the value of AstraZeneca PLC ADR from analyzing the firm fundamentals such as Current Valuation of 128.51 B, profit margin of 0.13 %, and Return On Equity of 0.17 as well as examining its technical indicators and probability of bankruptcy.
Enterprise Value
128.5 B
Undervalued
Today
63.80
Please note that AstraZeneca PLC's price fluctuation is very steady at this time. Calculation of the real value of AstraZeneca PLC ADR is based on 3 months time horizon. Increasing AstraZeneca PLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the AstraZeneca stock is determined by what a typical buyer is willing to pay for full or partial control of AstraZeneca PLC ADR. Since AstraZeneca PLC is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AstraZeneca Stock. However, AstraZeneca PLC's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  63.8 Real  76.43 Hype  63.8 Naive  66.88
The intrinsic value of AstraZeneca PLC's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AstraZeneca PLC's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
76.43
Real Value
77.96
Upside
Estimating the potential upside or downside of AstraZeneca PLC ADR helps investors to forecast how AstraZeneca stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AstraZeneca PLC more accurately as focusing exclusively on AstraZeneca PLC's fundamentals will not take into account other important factors:
Hype
Prediction
LowEstimatedHigh
62.2763.8065.33
Details
Naive
Forecast
LowNext ValueHigh
65.3466.8868.41
Details

AstraZeneca PLC Cash

4.84 Billion

AstraZeneca PLC Total Value Analysis

AstraZeneca PLC ADR is presently projected to have takeover price of 128.51 B with market capitalization of 128.51 B, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the AstraZeneca PLC fundamentals before making investing decisions based on enterprise value of the company

AstraZeneca PLC Investor Information

About 17.0% of the company shares are owned by institutions such as pension funds. The company recorded a loss per share of 0.36. AstraZeneca PLC ADR had not issued any dividends in recent years. The entity had 3:1 split on the 8th of April 1998. Based on the measurements of operating efficiency obtained from AstraZeneca PLC's historical financial statements, AstraZeneca PLC ADR is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.
Current ValueLast YearChange From Last Year 10 Year Trend
Total Cash From Operating Activities11.8 B11.3 B
Sufficiently Up
Slightly volatile
Operating Income3.2 B4.6 B
Way Down
Slightly volatile

AstraZeneca PLC Asset Utilization

One of the ways to look at asset utilization of AstraZeneca is to check how much profit was generated for every dollar of assets it reports. AstraZeneca PLC ADR utilizes its assets nearly 0.085 percent, earning 0.085 cents for each dollar of assets held by the firm. An expanding asset utilization signifies that the company is being more effective with each dollar of assets it shows. Put another way, asset utilization of AstraZeneca PLC shows how effective it operates for each dollar spent on its assets.
 
Covid

AstraZeneca PLC Profitability Analysis

The company reported the revenue of 51.21 B. Net Income was 5.96 B with profit before overhead, payroll, taxes, and interest of 35.73 B.

About AstraZeneca PLC Valuation

The stock valuation mechanism determines AstraZeneca PLC's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of AstraZeneca PLC ADR based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of AstraZeneca PLC. We calculate exposure to AstraZeneca PLC's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AstraZeneca PLC's related companies.
Last ReportedProjected for Next Year
Gross Profit24.5 B21.1 B

Additional Tools for AstraZeneca Stock Analysis

When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.